| Product Code: ETC7636159 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Ireland Opioid Receptor Agonist Market Overview |
3.1 Ireland Country Macro Economic Indicators |
3.2 Ireland Opioid Receptor Agonist Market Revenues & Volume, 2021 & 2031F |
3.3 Ireland Opioid Receptor Agonist Market - Industry Life Cycle |
3.4 Ireland Opioid Receptor Agonist Market - Porter's Five Forces |
3.5 Ireland Opioid Receptor Agonist Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.6 Ireland Opioid Receptor Agonist Market Revenues & Volume Share, By Receptor Binding, 2021 & 2031F |
3.7 Ireland Opioid Receptor Agonist Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.8 Ireland Opioid Receptor Agonist Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 Ireland Opioid Receptor Agonist Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.10 Ireland Opioid Receptor Agonist Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Ireland Opioid Receptor Agonist Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of chronic pain conditions in Ireland |
4.2.2 Growing awareness and acceptance of opioid therapy for pain management |
4.2.3 Rise in geriatric population requiring pain relief medications |
4.2.4 Technological advancements in opioid receptor agonist formulations |
4.2.5 Government initiatives to improve access to pain management treatments |
4.3 Market Restraints |
4.3.1 Stringent regulations and guidelines for opioid prescribing and dispensing |
4.3.2 Concerns over opioid abuse and addiction leading to stricter monitoring |
4.3.3 Limited reimbursement policies for opioid medications |
4.3.4 Growing preference for non-opioid alternatives for pain management |
4.3.5 Negative perceptions and stigma associated with opioid use |
5 Ireland Opioid Receptor Agonist Market Trends |
6 Ireland Opioid Receptor Agonist Market, By Types |
6.1 Ireland Opioid Receptor Agonist Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Drugs, 2021- 2031F |
6.1.3 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Fentanyl, 2021- 2031F |
6.1.4 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Codeine, 2021- 2031F |
6.1.5 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Morphine, 2021- 2031F |
6.1.6 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Buprenorphine, 2021- 2031F |
6.1.7 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Ireland Opioid Receptor Agonist Market, By Receptor Binding |
6.2.1 Overview and Analysis |
6.2.2 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Full Agonist, 2021- 2031F |
6.2.3 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Partial Agonist, 2021- 2031F |
6.3 Ireland Opioid Receptor Agonist Market, By Indication |
6.3.1 Overview and Analysis |
6.3.2 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Pain management, 2021- 2031F |
6.3.3 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Cough Suppression, 2021- 2031F |
6.3.4 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Diarrhoea suppression, 2021- 2031F |
6.3.5 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Ireland Opioid Receptor Agonist Market, By Route of Administration |
6.4.1 Overview and Analysis |
6.4.2 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Intravenous, 2021- 2031F |
6.4.3 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Subcutaneous, 2021- 2031F |
6.4.4 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Ireland Opioid Receptor Agonist Market, By End-Users |
6.5.1 Overview and Analysis |
6.5.2 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.5.3 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Homecare, 2021- 2031F |
6.5.4 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.5.5 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Others, 2021- 2031F |
6.6 Ireland Opioid Receptor Agonist Market, By Distribution Channel |
6.6.1 Overview and Analysis |
6.6.2 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.6.3 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.6.4 Ireland Opioid Receptor Agonist Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
7 Ireland Opioid Receptor Agonist Market Import-Export Trade Statistics |
7.1 Ireland Opioid Receptor Agonist Market Export to Major Countries |
7.2 Ireland Opioid Receptor Agonist Market Imports from Major Countries |
8 Ireland Opioid Receptor Agonist Market Key Performance Indicators |
8.1 Number of prescriptions for opioid receptor agonists |
8.2 Patient satisfaction with opioid therapy for pain management |
8.3 Rate of opioid-related adverse events |
8.4 Utilization of telemedicine for opioid therapy consultations |
8.5 Adoption rate of abuse-deterrent opioid formulations |
9 Ireland Opioid Receptor Agonist Market - Opportunity Assessment |
9.1 Ireland Opioid Receptor Agonist Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.2 Ireland Opioid Receptor Agonist Market Opportunity Assessment, By Receptor Binding, 2021 & 2031F |
9.3 Ireland Opioid Receptor Agonist Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.4 Ireland Opioid Receptor Agonist Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.5 Ireland Opioid Receptor Agonist Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.6 Ireland Opioid Receptor Agonist Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Ireland Opioid Receptor Agonist Market - Competitive Landscape |
10.1 Ireland Opioid Receptor Agonist Market Revenue Share, By Companies, 2024 |
10.2 Ireland Opioid Receptor Agonist Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here